BioCina CEO Ian Wisenberg
October 7, 2021 12:19 PM EDT
Manufacturing

BioCi­na com­pletes takeover of Pfiz­er-owned Aus­tralia plant; Cam­brex adds space at NC site for small mol­e­cules

Josh Sullivan

San Diego CD­MO BioCi­na has fi­nal­ized the fi­nal tran­si­tion of its takeover of an Aus­tralian man­u­fac­tur­ing site to boost its mR­NA

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

It's been three months with­out a biotech IPO

A service from the Financial Times